125 related articles for article (PubMed ID: 16945481)
1. Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma.
Mulaomerović A; Halilbasić A; Cickusić E; Zavasnik-Bergant T; Begić L; Kos J
Cancer Lett; 2007 Apr; 248(2):192-7. PubMed ID: 16945481
[TBL] [Abstract][Full Text] [Related]
2. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis.
Kos J; Krasovec M; Cimerman N; Nielsen HJ; Christensen IJ; Brünner N
Clin Cancer Res; 2000 Feb; 6(2):505-11. PubMed ID: 10690531
[TBL] [Abstract][Full Text] [Related]
3. Serum cystatin C in patients with head and neck carcinoma.
Strojan P; Svetic B; Smid L; Kos J
Clin Chim Acta; 2004 Jun; 344(1-2):155-61. PubMed ID: 15149884
[TBL] [Abstract][Full Text] [Related]
4. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Tumminello FM; Flandina C; Crescimanno M; Leto G
Biomed Pharmacother; 2008 Feb; 62(2):130-5. PubMed ID: 17728092
[TBL] [Abstract][Full Text] [Related]
5. Cysteine proteinase inhibitor level in tumor and normal tissues in control and cured mice.
Poteryaeva ON; Falameyeva OV; Korolenko TA; Kaledin VI; Djanayeva SJ; Nowicky JW; Sandula J
Drugs Exp Clin Res; 2000; 26(5-6):301-6. PubMed ID: 11345042
[TBL] [Abstract][Full Text] [Related]
6. The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer.
Nishikawa H; Ozaki Y; Nakanishi T; Blomgren K; Tada T; Arakawa A; Suzumori K
Gynecol Oncol; 2004 Mar; 92(3):881-6. PubMed ID: 14984956
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck.
Strojan P; Budihna M; Smid L; Svetic B; Vrhovec I; Skrk J
Neoplasma; 2001; 48(1):66-71. PubMed ID: 11327540
[TBL] [Abstract][Full Text] [Related]
8. [Cystatin C as a marker of glomerular filtration rate in patients with ovarian cancer].
Bodnar L; Wcisło GB; elichowski G; Raczka A; Wańkowicz Z; Szczylik C
Pol Merkur Lekarski; 2008 Apr; 24(142):307-11. PubMed ID: 18634361
[TBL] [Abstract][Full Text] [Related]
9. Cystatins in non-small cell lung cancer: tissue levels, localization and relation to prognosis.
Werle B; Schanzenbächer U; Lah TT; Ebert E; Jülke B; Ebert W; Fiehn W; Kayser K; Spiess E; Abrahamson M; Kos J
Oncol Rep; 2006 Oct; 16(4):647-55. PubMed ID: 16969475
[TBL] [Abstract][Full Text] [Related]
10. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
[TBL] [Abstract][Full Text] [Related]
11. Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as a new marker of renal function.
Tanaka A; Suemaru K; Otsuka T; Ido K; Nishimiya T; Sakai I; Hasegawa H; Inoue T; Murase M; Yasukawa M; Araki H
Ther Drug Monit; 2007 Apr; 29(2):261-4. PubMed ID: 17417082
[TBL] [Abstract][Full Text] [Related]
12. Increased plasma levels of cystatin C and transforming growth factor-beta1 in patients with coronary artery ectasia: can there be a potential interaction between cystatin C and transforming growth factor-beta1.
Yetkin E; Acikgoz N; Sivri N; Tekin GO; Yagmur J; Aksoy Y; Turhan H
Coron Artery Dis; 2007 May; 18(3):211-4. PubMed ID: 17429295
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer.
Zore I; Krasovec M; Cimerman N; Kuhelj R; Werle B; Nielsen HJ; Brünner N; Kos J
Biol Chem; 2001 May; 382(5):805-10. PubMed ID: 11517934
[TBL] [Abstract][Full Text] [Related]
14. GFR estimated from cystatin C versus creatinine in children born small for gestational age.
Franco MC; Nishida SK; Sesso R
Am J Kidney Dis; 2008 Jun; 51(6):925-32. PubMed ID: 18455848
[TBL] [Abstract][Full Text] [Related]
15. Cystatin C in sera of patients with aggressive non-Hodgkin B-cell lymphoma.
Softić A; Begić L; Halilbasić A; Kos J
Med Glas (Zenica); 2011 Feb; 8(1):97-100. PubMed ID: 21263405
[TBL] [Abstract][Full Text] [Related]
16. Is serum cystatin-C a reliable marker for metabolic syndrome?
Servais A; Giral P; Bernard M; Bruckert E; Deray G; Isnard Bagnis C
Am J Med; 2008 May; 121(5):426-32. PubMed ID: 18456039
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory markers and the progression of IgA glomerulonephritis.
Kaartinen K; Syrjänen J; Pörsti I; Hurme M; Harmoinen A; Pasternack A; Huhtala H; Mustonen J
Nephrol Dial Transplant; 2008 Apr; 23(4):1285-90. PubMed ID: 17986475
[TBL] [Abstract][Full Text] [Related]
18. Serum cystatin C as an endogenous marker of renal function in patients with chronic kidney disease.
Hojs R; Bevc S; Ekart R; Gorenjak M; Puklavec L
Ren Fail; 2008; 30(2):181-6. PubMed ID: 18300118
[TBL] [Abstract][Full Text] [Related]
19. Glomerular filtration rate as measured by serum cystatin C is an important determinant of plasma homocysteine and serum methylmalonic acid in the elderly.
Lewerin C; Ljungman S; Nilsson-Ehle H
J Intern Med; 2007 Jan; 261(1):65-73. PubMed ID: 17222169
[TBL] [Abstract][Full Text] [Related]
20. Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration.
Jaroszewicz J; Wiercinska-Drapalo A; Lapinski TW; Prokopowicz D; Rogalska M; Parfieniuk A
Antivir Ther; 2006; 11(5):641-5. PubMed ID: 16964834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
